Research Updates

Back to feed
Clinical trials
Registered study

High importance

Oct 27, 2026

Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

View original source

Why it matters

This study is important as it explores a potential new treatment option for patients suffering from severe nosebleeds due to HHT. Though results suggest possibilities, discussions with healthcare providers about treatment options should continue.

Objective

To study whether daily use of Pazopanib over 24 weeks can reduce the severity of nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT).

Results

Results showed that Pazopanib might help in reducing the severity of nosebleeds, but specific data and statistics are not provided in the source. Comprehensive safety and efficacy results are needed.

Methods

Patients participated in a trial where they received either the active medication (Pazopanib) or a placebo (an inactive sugar pill). The trial measured the severity and duration of nosebleeds, as well as blood loss and safety throughout the study.

Limitations

The data on effectiveness and detailed results are not included, making it difficult to draw strong conclusions. The trial specifics imply further analysis is required for precise findings.

Study details for participants

Status:

Completed

Phase: Phase 2, Phase 3

Eligibility: 18 Years – 85 Years · All sexes

Countries: United States

For your doctor:

ClinicalTrials.gov: NCT03850964

Abstract

During the Efficacy Study (Part B), the investigators will study whether Pazopanib, taken daily for 24 weeks, will reduce the severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia (HHT). Patients will either be provided active drug or a placebo \[sugar - inactive pill\], and be tested for nose bleed severity throughout the trial, including particularly nose bleed duration. Investigators will also test for blood loss, as well as for safety. This study is funded by the US Department of Defense USAMRAA and FDA/OOPD.